Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
Brand Names: Delstrigo
Methodology & AI Transparency ⓘ
Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate (100 mg/1 / 300 mg/1 Tablet, Film Coated; NDC 0006-5007) as a oral-route human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor formulation manufactured/labeled by Merck Sharp & Dohme LLC when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
- 2 Real-world patient consensus: Zero-PHI community consensus: 78% favorable across 14 logged regimens (Delstrigo).
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($90.6516/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate: nausea (9.1%), headache (7.4%), dizziness (6.3%).
Ask our AI Specialists anything about Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate (100 mg/1 / 300 mg/1 Tablet, Film Coated; NDC 0006-5007) as a oral-route human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor formulation manufactured/labeled by Merck Sharp & Dohme LLC when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate exerts selective human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor pharmacodynamic activity across 100 mg/1 / 300 mg/1 Tablet, Film Coated (oral-route route, manufactured/labeled by Merck Sharp & Dohme LLC), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 0006-5007).
Pharmacokinetic profiling of Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate demonstrates an elimination half-life of Mean elimination half-life of 4 to 8 hours across adult Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate dosing with Oral fraction absorbed ranges from 63% to 75% (Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate 100) systemic bioavailability; clearance proceeds via dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of doravirine, lamivudine, and tenofovir disoproxil fumarate, reaching clinical onset within oral tmax achieved within 2 to 3 hours following doravirine, lamivudine, and tenofovir disoproxil fumarate ingestion.
Titration schedules for Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate (100 mg/1 / 300 mg/1 Tablet, Film Coated → 100 mg → 300 mg/1 Tablet) require excluding contraindicated in patients with prior serious allergic response to doravirine, lamivudine, and tenofovir disoproxil fumarate (ndc 0006-5007); severe baseline organ impairment where doravirine, lamivudine, and tenofovir disoproxil fumarate accumulation exceeds safe therapeutic margins; real-world patient logs highlight nausea (9.1% of reports), headache (7.4% of reports), dizziness (6.3% of reports) alongside a 78.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate (NDC 0006-5007)
- Severe baseline organ impairment where Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (14 Reports)
Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD: What a 502-Participant Study Found In DRIVE-FORWARD and DRIVE-AHEAD, the development of resistance to doravirine was uncommon (genotypic 1.3%; phenotypic 1.0%) and occurred mainly during the first 48 weeks of treatment. Journal of acquired immune deficiency syndromes (1999) • 2026-03-01 • Phase III Randomized Trial | N = 502 | 93/100 | PMID 41129125 ↗ |
| New Insights on Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral: What a 1,227-Participant Study Found Baseline NNRTI RAMs and M184I/V in proviral DNA did not impact virologic outcomes through 48 weeks after switching to DOR/ISL (100/0.25 mg). The Journal of infectious diseases • 2026-09-23 • Phase III Randomized Trial | N = 1,227 | 90/100 | PMID 42213454 ↗ |
| Can This Approach Help? Inside the Latest Research on Brief Report: Resolution of Neuropsychiatric side effects After Switching to a In both trial extensions, NPAEs persisted in 3%-4% of participants 96 weeks after switching to a DOR-based regimen, possibly representing the background rate for these events. Journal of acquired immune deficiency syndromes (1999) • 2025-05-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39748155 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of doravirine/islatravir in heavily treatment-experienced DOR/ISL plus OBT improved HIV-1 suppression in HTE adults living with HIV-1 and was generally well tolerated. AIDS (London, England) • 2026-02-01 • Phase III Randomized Trial | N = 100 | 88/100 | PMID 41037024 ↗ |
| Can This Approach Help? Inside the Latest Research on Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Of 734 participants randomized, 728 received study drugs and were included in analyses. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-07-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33336698 ↗ |
Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $90.6516/unit (~$2719.55/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate RxNorm Concept ID | RXN-00065007-2636 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $90.6516 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate integrating DailyMed SPL (2026-07-01), CMS NADAC ($90.6516/unit), and 14 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate community threads and patient logs by age, biological sex, dosage, and treatment duration.